OncoMatch/Clinical Trials/NCT03779854
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
Is NCT03779854 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for acute biphenotypic leukemia.
Treatment: Thiotepa · Fludarabine · Cyclophosphamide · Busulfan · Tacrolimus · Methotrexate — This phase II trial studies how well naive T-cell depletion works in preventing chronic graft-versus-host disease in children and young adults with blood cancers undergoing donor stem cell transplant. Sometimes the transplanted white blood cells from a donor attack the body's normal tissues (called graft versus host disease). Removing a particular type of T cell (naive T cells) from the donor cells before the transplant may stop this from happening.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Myelodysplastic Syndrome
Non-Hodgkin Lymphoma
Myeloproliferative Neoplasm
Prior therapy
Must have received: cytotoxic chemotherapy
has received cytotoxic induction chemotherapy (excluding small molecule inhibitors and de-methylating agents)
Cannot have received: allogeneic or autologous hematopoietic cell transplant
Prior allogeneic or autologous HCT
Lab requirements
Kidney function
Serum creatinine within normal range for age; if outside normal, CrCl > 40 mL/min/1.73m^2
Liver function
Total bilirubin <= 2 x ULN (unless value(s) > 2 x ULN are disease- or medication-related); ALT, AST <= 2 x ULN (unless value(s) > 2 x ULN are disease- or medication-related)
Cardiac function
Left ventricular ejection fraction (LVEF) at rest >= 40%
Total bilirubin <= 2 x ULN (unless value(s) > 2 x ULN are disease- or medication-related). ALT, AST <= 2 x ULN (unless value(s) > 2 x ULN are disease- or medication-related). Serum creatinine within normal range for age; if outside normal, CrCl > 40 mL/min/1.73m^2. Left ventricular ejection fraction (LVEF) at rest >= 40%.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Children's Hospital of Los Angeles · Los Angeles, California
- Children's National Medical Center · Washington D.C., District of Columbia
- Children's Healthcare of Atlanta · Atlanta, Georgia
- University of Iowa/Holden Comprehensive Cancer Center · Iowa City, Iowa
- Dana Farber / Boston Children's Hospital · Boston, Massachusetts
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify